bristol Myers Squibb Bets $1.5 Billion on ‘Alive CAR T’ Revolution with Orbital Therapeutics Acquisition
Table of Contents
A groundbreaking acquisition signals a major shift in cell therapy, potentially expanding access and scalability through in-vivo reprogramming of immune cells.
On October 10th, 2025, Bristol myers Squibb (BMS) announced its plan to acquire Orbital Therapeutics for $1.5 billion in cash,a decisive move that positions the pharmaceutical giant at the forefront of the rapidly evolving “alive CAR T” sector. Orbital Therapeutics, headquartered in Cambridge, Massachusetts, has pioneered a next-generation RNA platform designed to reprogram immune cells inside the body – a stark contrast to the traditional method of engineering cells in a laboratory setting.
The Promise of In-Vivo CAR T Therapy
Central to the acquisition is Orbital’s lead investigational treatment, OTX 201. This therapy utilizes circular RNA delivered via lipid nanoparticles to encode a CD19-targeted CAR, with the ultimate goal of creating CAR-expressing cells directly within the patient’s body. This innovative approach has the potential to fundamentally reshape the cell therapy landscape by eliminating the complexities and logistical hurdles associated with external manufacturing.
Traditional CAR T therapy is a multi-step process. It requires collecting a patient’s T cells, genetically modifying them in a specialized facility, expanding them to therapeutic numbers, and reinfusing them back into the patient. This process is not onyl time-consuming and expensive but also limits access to patients at specialized centers.
In vivo CAR T therapy, however, offers a dramatically different paradigm. Instead of relying on engineered cells, this method delivers genetic instructions directly to the patient, enabling their own cells to produce the CAR within their bodies. This could substantially reduce costs, shorten treatment timelines, and broaden accessibility to a much larger patient population.
Orbital’s Technology: RNA and Lipid Nanoparticles
Orbital’s platform centers on optimized circular and linear RNA,with preclinical data demonstrating sufficient CAR expression in primates sufficient for immune reset applications. If these promising results translate to human trials, the therapy could usher in a new era of scalable and repeatable immune reprogramming.
Industry Implications and Market Outlook
The implications of this acquisition extend far beyond BMS. The move is expected to have a ripple effect across the pharmaceutical industry and the broader cell therapy market.
Specifically, the acquisition could lead to:
- Increased patient access to CAR T therapies, eliminating the need for specialized treatment centers.
- A shift in focus, with autoimmune diseases becoming a major frontier for CAR T therapy, rather than a secondary request.
- The potential for RNA-based cell programming to outperform traditional cell engineering methods, offering easier dosing, scalable manufacturing, and the possibility of redosing.
- Increased activity in the pharmaceutical sector,with competing companies potentially pursuing similar acquisitions or platform partnerships.
One analyst noted that “the fact that BMS paid a premium for a preclinical company signals the level of confidence in alive CAR T as a future foundational technology.”
BMS is making a calculated bet that the next generation of cell therapy will not depend on external manufacturing facilities. Instead, it will rely on programmable RNA delivered directly into the patient. This approach holds the potential to make CAR T therapy more accessible, more scalable, and better suited for treating chronic diseases affecting millions worldwide.
If clinical data confirms the preclinical promise, the acquisition of Orbital Therapeutics may be remembered as a defining moment in the evolution of cell therapy. It represents a basic shift – from complex ex vivo processes to a new model where the human body itself becomes the production site for therapeutic immune cells.
To learn more about the rapidly evolving CAR-T industry, view the “Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2025.”
